Back to search results

Study of Intracranial Venous Blood Sampling for Brain Cancer Diagnosis

This study is looking at a new way to diagnose brain cancers, specifically high-grade glioma (a type of aggressive brain tumor). Researchers want to see if taking blood samples directly from veins inside the brain (intracranial venous blood sampling) is safe and can provide the same detailed information about the tumor as a traditional surgical biopsy. This method is called a "liquid biopsy." The study will also explore if temporarily opening the blood-brain barrier (a protective layer around the brain) using a medicine called mannitol helps get even more accurate information. You might be able to join if you are over 18 and have suspected or confirmed high-grade glioma and are already scheduled for a diagnostic cerebral angiogram. The main goal is to check for safety and any side effects.

Study design
This is an observational study with a planned enrollment of 20 participants. It is not specified if it is randomized or blinded.
What's involved
Participants will undergo blood sampling via IV. The study will last for an average of 1 year.
Compensation
Not stated in the trial record.
Follow-up
Safety and adverse events will be measured through study completion, an average of 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07467109

A Study to Evaluate the Safety and Efficacy of Intracranial Venous Blood Sampling for Liquid Biopsy in the Diagnosis of Brain Cancers

Not Yet Recruiting
Not specifiedAges 18+Observational
M.D. Anderson Cancer Center
~20 participants
Updated 2026-03-19 on ClinicalTrials.gov
What's tested:blood sampling

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
safety and adverse events (AEs).
Measured over Through study completion; an average of 1 year

Conditions

Intracranial Venous Blood
Brain Cancers
Liquid Biopsy
Evaluate the Safety

Explore related trials

Glioma

Where it's being run

1 sites across 1 states
Texas1

Study leadership

  • Christopher C Young, MD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center

Who to contact

Christopher C Young, MD
[email protected]
713-745-4243
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

Severe contrast allergy
Acute/chronic renal dysfunction with eGFR \< 45 ml/min and Cr ≤ 1.5 mg/dL 3. For participants undergoing surgery, refractory coagulopathy or thrombocytopenia which cannot be corrected defined as:
Platelets ≤100,000/mcL
International Normalized Ratio ≤ 1.7 4. Subjects that have a known high risk in monitored anesthetic care or general anesthesia assessed by the treating physician. 5. Anatomic considerations: based on cross-sectional imaging such as CT angiogram of the head and neck, the anatomy for arterial and venous vascular access is deemed unsuitable for endovascular access such as high-grade carotid artery stenosis, absent or occluded internal jugular veins, sigmoid sinuses and/or transverse sinuses. 6. Participants with clinical cerebral edema evidenced from altered mental status 7. Pregnant women due to risk of radiation exposure to the fetus, as determined by pregnancy urinalysis or serum analysis test during screening. 8. Subjects with psychiatric illness/social situations that would limit compliance with study requirements at the physician's discretion.

What this trial measures

  • safety and adverse events (AEs).Through study completion; an average of 1 year

    Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0